06/22/22 7:30 AMNasdaq : BRTX clinical triallow floatBioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinicalRHEA-AIneutral
06/13/22 7:00 AMNasdaq : BRTX clinical triallow floatBioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced site initiation forRHEA-AIneutral
04/29/22 8:00 AMNasdaq : BRTX clinical triallow floatBioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc DiseaseBioRestorative Therapies, Inc. (the “Company” or “ BioRestorative ”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem cell-based therapies, today announced that it is hosting a Principal Investigators Meeting inRHEA-AIneutral
04/18/22 8:00 AMNasdaq : BRTX clinical triallow floatBioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc DiseaseBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has selected 10 of its 15 clinical sites for its Phase 2 clinical trialRHEA-AIneutral
04/04/22 8:00 AMNasdaq : BRTX low floatBioRestorative Therapies Announces cGMP Cell Manufacturing Facility CertificationBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, todayRHEA-AIneutral
03/10/22 8:00 AMNasdaq : BRTX low floatBioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® ProgramBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a research collaboration agreement with Dr. Tore Bengtsson,RHEA-AIneutral
02/16/22 8:30 AMNasdaq : BRTX low floatBioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc ProgramBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stemRHEA-AIneutral
02/07/22 9:00 AMNasdaq : BRTX clinical triallow floatBioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection UnderwayBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (N ASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it hasRHEA-AIneutral
02/07/22 7:45 AMNasdaq : BRTX low floatBioRestorative Therapies to Ring Nasdaq Stock Market Closing BellBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today announced that Lance Alstodt, BioRestorative’s Chairman and CEO, along with Francisco Silva,RHEA-AIneutral
02/02/22 8:00 AMNasdaq : BRTX low floatBioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP PortfolioBioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a life sciences company focused on stem cell-based therapies, todayRHEA-AIneutral